Custom synthesis | Naphthyridine | Pyrimidine | Indoline |
Competitive APIs

Daclatasvir 1009119-64-5

Daclatasvir 1009119-64-5
Daclatasvir (formerly BMS-790052, trade name Daklinza) is a drug for the treatment of hepatitis C (HCV). It was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daklinza gained its FDA approval on July 24, 2015 in the United States; it is approved for Hepatitis C genotype 3 infections.

GMP for Daclatasvir is not available yet, DMF for Daclatasvir is under preparation
 
Disclaimer:Those products (Daclatasvir 1009119-64-5) are for lab analytical & research purposes only.